Safety of percutaneous left atrial appendage closure with the amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation
- 11 December 2013
- journal article
- valvular and-structural-heart-diseases
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 83 (5) , 796-802
Abstract
Objective: To evaluate the safety of percutaneous left atrial appendage (LAA) closure with the Amplatzer Cardiac Plug (ACP) in patients with nonvalvular atrial fibrillation (AF) who are not eligible for oral anticoagulation with warfarin.Background: Anticoagulation is the treatment of choice for prevention of strokes in patients with AF, but some patients have contraindications to anticoagulation.Methods: A total of 60 patients with a CHA2DS2‐VASc score of at least 1 and contraindications to warfarin who underwent percutaneous LAA closure with the ACP were included. Stroke risk assessment was performed with the CHADS2 and CHA2DS2‐VASc score and the bleeding risk was calculated with the HAS‐BLED‐score. Follow‐up included office visits, telephone inquiries, and mail contact.Results: Mean CHADS2‐, CHA2DS2‐VASc‐, and HAS‐BLED scores were 2.6 (± 1.4), 4.3 (± 1.7), and 3.3 (± 1.0), respectively. Twenty‐five percent had a history of previous bleeding without oral anticoagulation and 63.3% while receiving oral anticoagulation. In 36.7% other contraindications to warfarin were present. Procedural success was achieved in 95%. Mean follow‐up time was 1.8 (1.0–2.8) years. The estimated annual stroke risk based on the CHADS2‐score was 5.8%. The estimated annual bleeding risk on warfarin based on the HAS‐BLED score was 3.7%. During follow‐up, the annual incidence of stroke was 0%. Major bleeding complications occurred in 1.9% annually.Conclusions: Percutaneous LAA closure with the ACP in patients with contraindications to oral anticoagulation is safe. The stroke and bleeding risk after percutaneous LAA closure is lower than predicted by conventional risk scores.Keywords
This publication has 23 references indexed in Scilit:
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on ThrombosisEP Europace, 2011
- 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2011
- Transcatheter closure of the left atrial appendage: Initial experience with the amplatzer cardiac plug deviceCatheterization and Cardiovascular Interventions, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Hospitalized Patients With Atrial Fibrillation and a High Risk of Stroke Are Not Being Provided With Adequate AnticoagulationJACC, 2005
- Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial FibrillationJACC, 2005
- Lifetime Risk for Development of Atrial FibrillationCirculation, 2004
- Percutaneous Left Atrial Appendage Occlusion (PLAATO) for Preventing CardioembolismCirculation, 2002
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991